T3 Defense Inc. (DFNS) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on events occurring on June 24, 2026, regarding the completion of a special meeting of stockholders for T3 Defense Inc. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbols DFNS (Common Stock) and DFNSW (Warrants).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and capital structure actions rather than financial performance metrics.
Material Changes and Corporate Actions
At the special meeting, 35,716,531 shares (59.26% of the 60,270,525 outstanding shares) were present or represented by proxy, establishing a quorum. The following proposals were approved by a majority of shares present:
- Warrant Issuance Approval: Authorized the issuance of common stock upon the exercise of restricted warrants issued in connection with the February 2026 Private Placement to comply with Nasdaq Listing Rules.
- Preferred Stock Conversion Approval: Authorized the issuance of common stock upon the conversion of Series B Convertible Preferred Stock issued in the February 2026 Private Placement, as required by Nasdaq Listing Rule 5635(d).
- Reverse Stock Split Authority: Granted the Board of Directors discretionary authority for 18 months to amend the certificate of incorporation to authorize a reverse stock split. The authorized ratio range is from one-for-two to one-for-two hundred fifty, with the specific ratio to be determined by the Board.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of complying with Nasdaq listing requirements. The primary contingency addressed is the potential implementation of a reverse stock split to maintain listing standards.
Key Facts for Investor Verification
- Verify the specific reverse stock split ratio if the Board exercises its new authority within the next 18 months.
- Monitor the dilution impact from the conversion of Series B Preferred Stock and the exercise of warrants from the February 2026 Private Placement.
- Review the Proxy Statement filed on June 1, 2026, for detailed terms of the approved proposals.
- Confirm the company's continued compliance with Nasdaq listing requirements following these approvals.